Physician profile
Samer Farah
NPI 1790746220
$3,111.20
in general payments reported to CMS, 2019-2025
22 companies · $546 in 2025
The $546 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $23.03 · 2021: $322 · 2022: $307 · 2023: $465 · 2024: $927 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,937.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $354.83 | 2024-2025 | Rocklatan, Tryptyr, Clareon Panoptix Pro |
| Alimera Sciences, INC. | $322.44 | 2021-2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $321.90 | 2019-2024 | Vabysmo |
| Abbvie INC. | $315.82 | 2022-2024 | |
| Biotissue Holdings INC. | $285.72 | 2024 | |
| Sight Sciences, INC. | $214.59 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Apellis Pharmaceuticals, INC. | $154.28 | 2023 | Syfovre |
| Astellas Pharma US INC | $148.50 | 2023-2025 | Izervay |
| Ani Pharmaceuticals, INC. | $143.12 | 2025 | Yutiq, Iluvien |
| Allergan, INC. | $123.66 | 2019 | |
| Aerie Pharmaceuticals, INC. | $119.67 | 2019 | |
| Oyster Point Pharma, INC. | $115.11 | 2023 | Tyrvaya |
| Regeneron Healthcare Solutions, INC. | $106.35 | 2024 | Eylea, Eylea Hd |
| Ocular Therapeutix, INC. | $95.18 | 2021 | |
| Ivantis, INC | $78.91 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $44.57 | 2021 | |
| Coherus Oncology, INC. | $34.27 | 2023 | |
| Thrombogenics, INC. | $29.24 | 2019 | |
| Biogen, INC. | $28.04 | 2023 | |
| Mallinckrodt Hospital Products INC. | $27.88 | 2021 | |
| Mallinckrodt Enterprises LLC | $24.09 | 2019 | |
| Spark Therapeutics, INC. | $23.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Farah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.